Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
NL0011832936
Tue, 28.06.2022
Cosmo Pharmaceuticals N.V.
Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices Agency). The review is expected to last approximately a ye [ … ]
Tue, 28.06.2022
Cosmo Pharmaceuticals N.V.
Dublin, Ireland – 28 June 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced that Ferring, our partner for Cortiment® MMX® (budesonide), submitted the NDA for Japan on June 23, 2022, and the application has been accepted by PMDA (Pharmaceuticals and Medical Devices Agency). The review is expected to last approximately a ye [ … ]
Fri, 27.05.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): AGMEGM
Cosmo Pharmaceuticals’ Shareholders approve all Agenda Items at Annual General Meeting FOR ELEVIEW® TO ALL COUNTRIES EXCEPT CANADA
27.05.2022 / 15:15
Press Release (PDF)
Dublin, Ireland – 27 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) today announced that its shar [ … ]
Tue, 03.05.2022
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Miscellaneous
COSMO ANNOUNCES EXPANDING THE AGREEMENT WITH MEDTRONIC FOR ELEVIEW(R) TO ALL COUNTRIES EXCEPT CANADA
03.05.2022 / 06:00
Press Release (PDF)
Dublin, Ireland - 3 May 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announces the expansion of the agreement wi [ … ]
Wed, 23.03.2022
Cosmo Pharmaceuticals N.V.
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland - 23 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') reports full-year 2021 results for the year ended 31 December 2021, confirms beating guidance, and, as previously announced, proposes a dividend of €0.95 per share at the next AGM on 27 May 2022.
Business [ … ]
Fri, 18.03.2022
Cosmo Pharmaceuticals N.V.
Dublin, Ireland - 18 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announced that Medtronic on 16 March 2022 issued the following release:
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced final findings from a randomized, international, multi-center study that confirmed the effectivene [ … ]
Wed, 16.03.2022
Cosmo Pharmaceuticals N.V.
Dublin, Ireland - 16 March 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') announced today that it will publish its full-year 2021 results on Wednesday, 23 March 2022 at 07:00 am CET ahead of the previously planned date (31 March 2022). Cosmo invites investors, financial analysts and business/life science journalists to a live vi [ … ]
Tue, 15.02.2022
Cosmo Pharmaceuticals N.V.
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland - 15 February 2022: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) ('Cosmo') today announced its preliminary unaudited results for 2021.
Total revenues of €65.1m vs guidance €60m - €64m
Operating profit of €7m - €10m vs guidance of €3m - €5m
Profit before taxes of €20m - €23m vs guida [ … ]
Thu, 30.12.2021
Cosmo Pharmaceuticals N.V.
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland - 30 December 2021: Cosmo Pharmaceuticals N.V. (SIX: COPN) ('Cosmo') today announced that Ms. Hazel Winchester has been appointed to the position of Head of Investor Relations and will take up the position on the 10th of January, 2022.
Ms. Winchester brings almost two decades of investor [ … ]
Fri, 17.12.2021
Cosmo Pharmaceuticals N.V.
Ad hoc announcement pursuant to Art. 53 LR
Dublin, Ireland and Lainate, Italy - 17 December 2021 - Cosmo Pharmaceuticals N.V. (SIX: COPN) ("Cosmo") and Cassiopea S.p.A. (SIX: SKIN) ("Cassiopea") announce the settlement of the public exchange offer by Cosmo in accordance with articles 125 et seq. of the Federal Act on Financial Markets Infrastructur [ … ]